Id |
Subject |
Object |
Predicate |
Lexical cue |
T667 |
0-2 |
Sentence |
denotes |
7. |
T668 |
3-56 |
Sentence |
denotes |
Pharmacology of Glycan-Related Anti-SARS-CoV-2 Agents |
T669 |
57-210 |
Sentence |
denotes |
The emerging CoV-pandemic requires therapeutic agents to block the recognition, binding, replication, amplification and propagation of the CoV in humans. |
T670 |
211-346 |
Sentence |
denotes |
Protease inhibitors, RNA synthase inhibitors and S2 inhibitors are potential targets, and several agents are currently being evaluated. |
T671 |
347-417 |
Sentence |
denotes |
Efficient therapeutic drugs are the most reliable option for patients. |
T672 |
418-554 |
Sentence |
denotes |
The first attachment step of the viral amplification cycle is initiated on the respiratory cell surfaces, driven by the viral S protein. |
T673 |
555-594 |
Sentence |
denotes |
This is a potential therapeutic target. |
T674 |
595-736 |
Sentence |
denotes |
Soon after the SARS-CoV-2 outbreak initiated, the CoV S glycoprotein was demonstrated to recognize ACE2 as a binding receptor on human cells. |
T675 |
737-834 |
Sentence |
denotes |
Human TMPRSS2 enzyme influences the CoV S glycoprotein activation, to facilitate virus infection. |
T676 |
835-921 |
Sentence |
denotes |
ACE2 binding and TMPRSS2 activation facilitate the CoVs to attach to human host cells. |
T677 |
922-1035 |
Sentence |
denotes |
Mouse, nonhuman primate and human cells have been analyzed using single-cell RNA new generation sequencing (NGS). |
T678 |
1036-1190 |
Sentence |
denotes |
For example, for human infection, CoVs can enter nasal goblet secretory cells, because these cells express the proteins required for SARS-CoV-2 infection. |
T679 |
1191-1281 |
Sentence |
denotes |
In the lungs, the proteins are stored in the alveoli like air sacs of type II pneumocytes. |
T680 |
1282-1358 |
Sentence |
denotes |
In the intestine, the two proteins are expressed in entero-epithelial cells. |
T681 |
1359-1424 |
Sentence |
denotes |
ACE2 gene expression correlates with the IFN-related genes [137]. |
T682 |
1425-1475 |
Sentence |
denotes |
ACE2 helps lung cells to tolerate cellular damage. |
T683 |
1476-1601 |
Sentence |
denotes |
Therefore, CoVs may evolutionally take advantage of the defense mechanisms of host cells, hijacking such host-borne proteins. |
T684 |
1602-1762 |
Sentence |
denotes |
In SARS-CoV-2, the ACE2 receptor is an attachment, entry and infection receptor into the cell, when the S glycoprotein is cleaved by a specific serine protease. |
T685 |
1763-1891 |
Sentence |
denotes |
SARS-CoV-2 infection is regulated by glycosylated SARS-CoV-2 viral particles and glycosylated ACE2 in the lung epithelial cells. |
T686 |
1892-1943 |
Sentence |
denotes |
RBD of the CoV S glycoprotein recognizes ACE2 [82]. |
T687 |
1944-2088 |
Sentence |
denotes |
Amino acid residues 442, 472, 479, 480 and 487 located on the receptor-binding motif (RBM) of the S glycoprotein RBD recognize human ACE2 [138]. |
T688 |
2089-2198 |
Sentence |
denotes |
Trimeric viral S glycoprotein is glycosylated and cleaved by a protease, furin, into two subunits, S1 and S2. |
T689 |
2199-2296 |
Sentence |
denotes |
Subunit S1 is further cleaved into the SA and SB domains and the SB domain recognizes human ACE2. |
T690 |
2297-2377 |
Sentence |
denotes |
The N-glycosylated S2 subunit is involved in virus-ACE2 complex formation [139]. |
T691 |
2378-2467 |
Sentence |
denotes |
Therefore, the glycosylated ACE2 receptor is a key molecule for virus binding and fusion. |
T692 |
2468-2541 |
Sentence |
denotes |
Plasma sera prepared from infected patients is an alternative medication. |
T693 |
2542-2632 |
Sentence |
denotes |
The WHO has suggested this trial since the 2014 Ebola epidemic and 2015 MERS-CoV outbreak. |
T694 |
2633-2676 |
Sentence |
denotes |
In addition, Mab therapy is another option. |
T695 |
2677-2804 |
Sentence |
denotes |
For example, LCA50 Mab mimics produced by modification of plasma antibodies isolated from MERS-CoV patients was valuable [140]. |
T696 |
2805-2924 |
Sentence |
denotes |
Low molecular molecules are being examined for anti-virus activities from alkaloids, glycan derivatives and terpenoids. |
T697 |
2925-3028 |
Sentence |
denotes |
Recently, anti-CoV drugs are being approached using molecular modeling, docking and simulation methods. |
T698 |
3029-3160 |
Sentence |
denotes |
Computation-assisted drugs via molecular modeling and docking toward drug targets are applied as anti-viral compounds against CoVs. |
T699 |
3161-3196 |
Sentence |
denotes |
They target human ACE2, PLpro (PDB: |
T700 |
3197-3233 |
Sentence |
denotes |
3e9s), the CoV main proteinase (PDB: |
T701 |
3234-3401 |
Sentence |
denotes |
6Y84), 3-chymotrypsin-like (3C-like protease; 3CLpro), RdRp, helicase, N7 methyltransferase, human DDP4, RBD, protease cathepsin L, type II TM Ser protease or TMPRSS2. |
T702 |
3402-3418 |
Sentence |
denotes |
CoV 3CLpro (PDB: |
T703 |
3419-3490 |
Sentence |
denotes |
6WX4) and the PLpro cleave the polyproteins to assemble virus proteins. |
T704 |
3491-3622 |
Sentence |
denotes |
For newborn RNA genomes, RdRp is used as a replicase for the complementary RNA strand synthesis, which uses the virus RNA template. |
T705 |
3624-3628 |
Sentence |
denotes |
7.1. |
T706 |
3629-3708 |
Sentence |
denotes |
N-Glycosylation Inhibition by Chloroquine (CLQ) and Hydroxychloroquine (CLQ-OH) |
T707 |
3709-3788 |
Sentence |
denotes |
CLQ and CLQ-OH are under investigation worldwide to treat COVID-19 (Figure 10). |
T708 |
3789-3933 |
Sentence |
denotes |
CLQ and its derivative CLQ-OH block CoV replication, amplification and spread in in vitro culture via inhibition of ACE2 receptor glycosylation. |
T709 |
3934-4078 |
Sentence |
denotes |
In HCoVs, interaction of the S glycoprotein with gangliosides initially occur as the first entry step during the replication cycle of the virus. |
T710 |
4079-4224 |
Sentence |
denotes |
CLQ and CLQ-OH have been alternative drugs for RA and several autoimmune diseases for 70 years, although they are anti-malaria prophylaxis drugs. |
T711 |
4225-4281 |
Sentence |
denotes |
CLQ-OH is an aminoquinoline with less toxicity than CLQ. |
T712 |
4282-4378 |
Sentence |
denotes |
CLQ-OH bears an N-hydroxyethyl side chain, which increases its solubility compared to CLQ [141]. |
T713 |
4379-4481 |
Sentence |
denotes |
CLQ-OH modulates activated immune cells via downregulation of TLR signaling and IL-6 production [142]. |
T714 |
4482-4570 |
Sentence |
denotes |
Clinical trials are also under consideration for the efficacy and safety of these drugs. |
T715 |
4571-4687 |
Sentence |
denotes |
Regarding the action mechanism(s), CLQ and CLQ-OH-mediated inhibition of ACE2 terminal glycosylation was considered. |
T716 |
4688-4874 |
Sentence |
denotes |
In in vitro Vero E6 cells, CLQ significantly inhibits SARS-CoV spread by interfering with ACE2 function, acting at the entry and post-entry steps of SARS-CoV-2 replication and infection. |
T717 |
4875-4981 |
Sentence |
denotes |
The binding affinity of ACE2 to S glycoprotein is simulated to be lowered by treatment with CLQ-OH or CLQ. |
T718 |
4982-5103 |
Sentence |
denotes |
CLQ may modify the binding affinity between ACE2 and S glycoprotein by alterations in ACE2 glycosylation or modification. |
T719 |
5104-5175 |
Sentence |
denotes |
CLQ-OH (EC50 0.72 μM) and CLQ (EC50, 5.47 μM) inhibit SARS-CoV-2 [143]. |
T720 |
5176-5413 |
Sentence |
denotes |
Using computer simulation techniques, CLQ and CLQ-OH have been suggested to recognize the enzymatic active site of the UDP-GlcNAc 2-epimerase, known as an essential enzyme in SA biosynthesis [144], blocking the sialylation of host cells. |
T721 |
5414-5619 |
Sentence |
denotes |
The mechanism underlying the glycosylation inhibition may support the antiviral properties of CLQ and CLQ-OH through interactions of CLQ or CLQ-OH with NDP-saccharide mutases or glycosyltransferases [145]. |
T722 |
5620-5764 |
Sentence |
denotes |
CLQ was reported to inhibit quinone reductase 2 [146], known as a catalytic mimetic or structural neighbor of UDP-GlcNAc 2-epimerases [147,148]. |
T723 |
5765-5956 |
Sentence |
denotes |
If CLQ or CLQ-OH inhibits SA synthesis, the inhibitory properties may support the antiviral activity of CLQ or CLQ-OH against SARS-CoVs because the SARS-CoV receptor ACE2 contains SA species. |
T724 |
5957-6075 |
Sentence |
denotes |
In fact, CLQ exhibits in vitro anti-SARS-CoV-1 activity via defective glycosylation of viral ACE2 in Vero cells [149]. |
T725 |
6076-6269 |
Sentence |
denotes |
In addition. the interference of CLQ or CLQ-OH with SA synthesis may broadly be applicable as an antiviral because the HcoVs or other orthomyxoviruses also utilize SAs as entry molecules [150]. |
T726 |
6270-6332 |
Sentence |
denotes |
However, the detailed mechanisms should be further elucidated. |
T727 |
6333-6428 |
Sentence |
denotes |
The CLQ treatment efficacy in Covid-19 patients has, however, not been conclusively determined. |
T728 |
6430-6434 |
Sentence |
denotes |
7.2. |
T729 |
6435-6506 |
Sentence |
denotes |
Interaction of Membrane Gangliosides in Lipid Rafts with CLQ and CLQ-OH |
T730 |
6507-6551 |
Sentence |
denotes |
Lipid rafts are also viral attachment sites. |
T731 |
6552-6870 |
Sentence |
denotes |
Viruses such as IBV, dengue virus, Ebola virus, hepatitis C virus, HIV, human herpes virus 6, measles virus, Newcastle disease virus, poliovirus, West Nile virus, foot-and-mouth disease virus, simian virus 40, rotavirus, influenza virus and Marburg virus also use lipid rafts for virus entry [151,152,153,154,155,156]. |
T732 |
6871-6997 |
Sentence |
denotes |
In avian CoV IBV, structural proteins of the IBV virus are co-localized with PM lipid rafts embedded with the ganglioside GM1. |
T733 |
6998-7130 |
Sentence |
denotes |
HCoV-229E entry is prevented by cholesterol depleted conditions because HCoV-229E clusters in caveolae-associated lipid rafts [157]. |
T734 |
7131-7280 |
Sentence |
denotes |
Caveolae of caveolin-1, -2 and -3 are cross-linked [158] and control the molecular distribution between rafts and caveolae in a regulatory mechanism. |
T735 |
7281-7350 |
Sentence |
denotes |
S protein-CD13 cross-linking occurs via CD13-caveolin-1 sequestering. |
T736 |
7351-7426 |
Sentence |
denotes |
HCoV-229E particles similarly exhibit a longitudinal distribution property. |
T737 |
7427-7503 |
Sentence |
denotes |
HCoV-229E-colocalized caveolin-1 undergoes the next step of virus infection. |
T738 |
7504-7624 |
Sentence |
denotes |
Caveolin-1 knockdown inhibited HCoV-229E endocytosis and entry and thus caveolin-1 is essential for HCoV-229E infection. |
T739 |
7625-7700 |
Sentence |
denotes |
TGEV also endocytoses by a clathrin-mediated mechanism in MDCK cells [159]. |
T740 |
7701-7805 |
Sentence |
denotes |
Other viruses including HCoV-OC43 also use an entry receptor sequestered to cross-linked caveolae [160]. |
T741 |
7806-7915 |
Sentence |
denotes |
In SARS-CoV, the first entry step to host cells needs ACE2 in intact lipid rafts by the S glycoprotein [151]. |
T742 |
7916-8032 |
Sentence |
denotes |
ACE2 is associated with caveolin-1 and GM1 in membrane rafts depending on its cell-type specific localization [161]. |
T743 |
8033-8178 |
Sentence |
denotes |
Raft integrity with cholesterol and ACE2 is necessary for SARS-CoV pseudovirus entry into Vero E6 cells and for SARS-CoV-microdomain-based entry. |
T744 |
8179-8276 |
Sentence |
denotes |
C-type lectin, CD209 L (L-SIGN), can also form lipid rafts and acts as a SARS-CoV receptor [162]. |
T745 |
8277-8461 |
Sentence |
denotes |
Information of the CoV entry pathways is important for therapeutic designation of SARS-CoV-targeting drugs, for example, if agents disrupt lipid-raft localization of the ACE2 receptor. |
T746 |
8462-8533 |
Sentence |
denotes |
CLQ binds the SAs and gangliosides in lipid rafts with a high affinity. |
T747 |
8534-8607 |
Sentence |
denotes |
Therefore, CLQ or CLQ-OH prevents the S glycoprotein–ganglioside binding. |
T748 |
8608-8701 |
Sentence |
denotes |
CLQ (or CLQ-OH) binding to SA consequently prevents S glycoprotein binding to host receptors. |
T749 |
8702-8781 |
Sentence |
denotes |
The N-terminal region of SARS-CoV-2 S glycoprotein interacts with gangliosides. |
T750 |
8782-8909 |
Sentence |
denotes |
A ganglioside-binding site (GBS) or ganglioside-binding domain (GBD) is present in the NTD of the S glycoprotein of SARS-CoV-2. |
T751 |
8910-9023 |
Sentence |
denotes |
Using molecular modeling and simulation technology, CLQ has been suggested to recognize the SAs and gangliosides. |
T752 |
9024-9066 |
Sentence |
denotes |
Human type Neu5Ac binds to CLQ and CLQ-OH. |
T753 |
9067-9115 |
Sentence |
denotes |
Thus, SAs are binding targets of CLQ and CLQ-OH. |
T754 |
9116-9214 |
Sentence |
denotes |
CLQ and CLQ-OH have two specific recognition sites in the polar sugar residues of ganglioside GM1. |
T755 |
9215-9320 |
Sentence |
denotes |
The first site is found at the tip of the sugar residues of GM1 with an interaction energy of −47 kJ/mol. |
T756 |
9321-9464 |
Sentence |
denotes |
The CLQ rings face the GalNAc residue of GM1, while the second site is in a large region of the sugar-ceramide junction and the sugar residues. |
T757 |
9465-9585 |
Sentence |
denotes |
Several amino acid residues of the S protein NTD, which are Phe-135, Asn-137 and Arg-158, recognize the ganglioside GM1. |
T758 |
9586-9742 |
Sentence |
denotes |
The S glycoprotein NTD-GM1 complex is suggested to form a trimolecular complex with two molecules of ganglioside GM1 anchored to the NTD of S protein [163]. |
T759 |
9743-9856 |
Sentence |
denotes |
The ACE2-binding RBD is suggested to be a potential GBS located on a differential site of the S glycoprotein NTD. |
T760 |
9857-9937 |
Sentence |
denotes |
The protein sequence interfacing surface of the NTD is the consensus GBDs [164]. |
T761 |
9938-10090 |
Sentence |
denotes |
The amino acids Gly, Pro and/or Ser residues found in GBD motifs are in the same 111–158 amino acids of the NTD as the ganglioside-attachment interface. |
T762 |
10091-10171 |
Sentence |
denotes |
The GBD is conserved throughout viral isolates from worldwide COVID-19 patients. |
T763 |
10172-10296 |
Sentence |
denotes |
The GBD potentially increases viral attachment ability to PM lipid rafts and contact between host ACE-2 and S protein [165]. |
T764 |
10297-10405 |
Sentence |
denotes |
The interaction between CLQ-OH and 9-O-acetyl-NeuAc is also similar to the 9-O-acetyl-NeuAc-CLQ interaction. |
T765 |
10406-10492 |
Sentence |
denotes |
The CLQ-OH OH group enhances the interaction of CLQ with SA via a hydrogen bond [163]. |
T766 |
10493-10664 |
Sentence |
denotes |
In conditions with CLQ or CLQ-OH derivative treatment, the S glycoprotein cannot bind to gangliosides in in silico studies, which are used to uncover the action mechanism. |
T767 |
10665-10734 |
Sentence |
denotes |
CLQ and CLQ-OH prevent the binding of S glycoprotein to gangliosides. |
T768 |
10735-10906 |
Sentence |
denotes |
The CLQ-SA complex is formed in a mixed surface and balls by the positioning of the negative charged COOH group of Neu5Ac and one of the two cationic charges of CLQ [163]. |
T769 |
10907-11002 |
Sentence |
denotes |
CoVs preferentially bind to 9-O-acetyl-NeuAc [60], differentiating with other viral properties. |
T770 |
11003-11144 |
Sentence |
denotes |
As CLQ interacts with the GM1 sugar part, the N-terminal domain of the S protein loses viral attachment capacity to the cell receptors [166]. |
T771 |
11145-11377 |
Sentence |
denotes |
The S protein NTD and the CLQ/CLQ-OH maintain the same position during GM1 binding, consequently preventing GM1 binding to the S protein and the drug at the same time, because the NTD and the CLQ/CLQ-OH simultaneously recognize GM1. |
T772 |
11378-11494 |
Sentence |
denotes |
Asn-167 forms a hydrogen bond with the GalNAc residue, whereas an aromatic Phe-135 stacks to the Glc residue of GM1. |
T773 |
11495-11654 |
Sentence |
denotes |
Therefore, the antiviral activities of CLQ and CLQ-OH is to block the interaction between the SARS-CoV-2 S glycoprotein and gangliosides on host cell surfaces. |
T774 |
11655-11782 |
Sentence |
denotes |
The lipid composition of host cell PM can also be a potential target for preventive and therapeutic drugs against such viruses. |